Share on

Asia Pacific Cell Fractionation Market Research Report – Segmented By Product, Type Of Cell, End User & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Trends & Growth Forecast (2024 to 2029)

Published: March, 2023
ID: 2542
Pages: 135
Formats: report pdf report excel report power bi report ppt

APAC Cell Fractionation Market Size (2024 to 2029)

The size of the Asia Pacific Cell Fractionation Market was valued at USD 0.84 Billion in 2024. This value is further estimated to be growing at a CAGR of 10.7% and worth USD 1.40 Billion by 2029.

The high prevalence of diseases, the increase in government funding for research and development activities, the growing focus on personalized medicine, and the expansion of the biopharmaceutical and biotechnology industries drive APAC cell fractionation. Government and corporate investments have expanded significantly to drive the manufacturing and supply of medical supplies needed to treat chronic diseases, expected to drive Asia Pacific market growth. There is a significant need in research laboratories and institutes, increasing as the number of cultured cells processed for commercially diagnostic and research purposes grow due to the increased number of chronic diseases and infectious diseases, which has helped improve overall drug demand. A crucial development in this area is the requirement to isolate subcellular proteins from cultivated cells.

Advancements are bolstering the uptake in the cell fractionation market in the APAC region in various equipment and reagents. The microelectronic industry's use of microfabrication has set the tone for the present wave of product innovation in the cell fractionation sector. Given its great promise in cell lysis and single-cell analysis, Microfluidics has attracted a lot of attention in recent years. Increased frequency of chronic diseases, advances in research infrastructure, and favorable regulations for cell-based research to create novel products all have the potential to augment market growth. Because of the relevance of cell-based research, several government agencies have expanded their support for the expansion of such studies. Many government agencies have offered financial assistance in investments, funds, and grants.

Some of the major impediments are a lack of experienced people, the high expense of cell-based research, and the survival of new entrants and small players. As a result, small businesses and entrants to the cell fractionation market face substantial difficulty. In addition, R&D and market launch of innovative items necessitate large sums of money. As a result, corporations must invest extensively to remain competitive in the market.

This research report has been segmented and sub-segmented the Asia Pacific Cell Fractionation Market into the following categories.

By Product:

  • Consumables
  • Reagents
    • Enzymes
    • Detergent Solutions
  • Beads
  • Disposables
  • Instruments
    • Sonicator
    • Homogenizer

By Cell Type: 

  • Microbial
  • Mammalian

By End User: 

  • Research Laboratories
  • Biopharmaceuticals
  • Biotechnology Companies

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

During the forecast period, the market in the Asia Pacific is expected to develop at the fastest rate. Government assistance for vaccine production, increased financing for cell-based research, cheap manufacturing costs, and the expanding focus of global market players on emerging Asian economies are all driving this industry's expansion. As a result, leading players in the plasma fractionation market will find Asia-Pacific a lucrative market. This is due to government bodies that control and supervise plasma collection, fractionation, and sales, which are the primary drivers of the plasma fractionation market.

Furthermore, rising incidences of medical problems such as high fever with thrombocytopenia syndrome (SFTS), hemophilia, and primary and secondary immunological deficiencies are driving the industry forward. For players in the cell fractionation market, China, Brazil, and India present significant opportunities. The rising frequency of chronic diseases, advancements in research infrastructure, and favorable regulations for cell-based research in emerging countries are all contributing factors. As a result, major industry players are expanding their presence in emerging markets such as China by constructing new facilities and R&D and innovation centers.

KEY MARKET PLAYERS:

Some of the notable companies operating in the Asia pacific cell fractionation market profiled in the report are Beckman Coulter, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., F. Hoffman-La Roche AG, Merck KGaA, Miltenyi Biotec, QIAGEN N., Qsonica and Thermo Fisher Scientific Inc.

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample